Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial
MELBOURNE, Australia, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, has commenced a Phase 1b/2a trial evaluating the safety and …